Health care stocks declined Thursday afternoon with the NYSE Health Care Index shedding 0.7% and the Health Care Select Sector SPDR Fund (XLV) falling 1.2%.
The iShares Biotechnology ETF (IBB) dropped 1%.
In corporate news, Novo Nordisk (NVO) Chief Executive Officer Lars Fruergaard Jorgensen said the company will feel the impact of President Donald Trump's threatened tariffs despite its investments in the US, according to media reports. Novo shares declined 3.4%.
Plus Therapeutics (PSTV) shares surged 98% after it said Thursday that its Rhenium obisbemeda radiotherapy has been granted orphan drug designation by the US Food and Drug Administration for treating leptomeningeal metastases in lung cancer patients.
BridgeBio Pharma (BBIO) shares were falling past 6% after KKR Genetic Disorder disclosed the sale of 6 million BridgeBio shares in a regulatory filing.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。